Dementia CME Series: Novel Treatments for Patients with Alzheimer's Disease
Starts On:
Fri, 9/7/18: 12:00 AM
Ends On:
Fri, 2/7/20: 12:00 AM
Type:
Internet Activity Enduring Material
CME Hours:
1
Description:
Novel Treatments for Patients with Alzheimer's Disease
Lawrence Honig, MD, PhD
Professor of Neurology
Columbia University
Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as 'disease-modifying' drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulation and cholesterol metabolism. It is important to discuss current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I–III trials.
Disclosures: Course Director/Planners: Drs. Carl Cohen and Michael Reinhardt - The members of the Planning Committee have no relevant financial relationships to disclose. Presenter disclosures: Dr. Lawrence Honig has disclosed the following: Consultant for : Eli Lily, BMS, & Miller communications. Research grants received from: BMS, Biogen, Eisai, Roche, Genentech, Johnson & Johnson, Eli Lily, Astra Zeneca, Tavax, Merck, & QR Pharma
How to Obtain Credit
1. To receive CME credits, view all of the presentations, which should take 1 hour of your time.
2. To obtain credit, a score of 70% or better is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME Credits within your Profile/CME History, which you can access at any time.
RELEASE DATE: 9/2018; VALID UNTIL:9/2020; LAST REVIEW: 2/2018;
Accreditation/Designation Statements:
The State University of New York (SUNY) Downstate Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
SUNY Downstate Medical Center designates this internet enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Social Workers
SUNY Downstate Medical Center is recognized by the New York State Education Department's State Board
for Social Work as an approved provider of continuing education for licensed social workers #SW-0469
Lawrence Honig, MD, PhD
Professor of Neurology
Columbia University
Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as 'disease-modifying' drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulation and cholesterol metabolism. It is important to discuss current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I–III trials.
Disclosures: Course Director/Planners: Drs. Carl Cohen and Michael Reinhardt - The members of the Planning Committee have no relevant financial relationships to disclose. Presenter disclosures: Dr. Lawrence Honig has disclosed the following: Consultant for : Eli Lily, BMS, & Miller communications. Research grants received from: BMS, Biogen, Eisai, Roche, Genentech, Johnson & Johnson, Eli Lily, Astra Zeneca, Tavax, Merck, & QR Pharma
How to Obtain Credit
1. To receive CME credits, view all of the presentations, which should take 1 hour of your time.
2. To obtain credit, a score of 70% or better is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME Credits within your Profile/CME History, which you can access at any time.
RELEASE DATE: 9/2018; VALID UNTIL:9/2020; LAST REVIEW: 2/2018;
Accreditation/Designation Statements:
The State University of New York (SUNY) Downstate Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
SUNY Downstate Medical Center designates this internet enduring activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Social Workers
SUNY Downstate Medical Center is recognized by the New York State Education Department's State Board
for Social Work as an approved provider of continuing education for licensed social workers #SW-0469
Objectives:
After viewing, participants will be able to implement current symptomatic treatments and discuss new potential disease-modifying therapies for AD that are currently being studied in phase I–III trials.
Target Audience: primary care and specialist physicians, nurses, social workers & other HCPs
Target Audience: primary care and specialist physicians, nurses, social workers & other HCPs
Sponsor:
This lecture is being sponsored by an eduational grant from NYS Department of Health Center for Alzheimer Disease.
